MY138883A - Use of asiatic acid for treatment of cencer - Google Patents

Use of asiatic acid for treatment of cencer

Info

Publication number
MY138883A
MY138883A MYPI20003987A MYPI20003987A MY138883A MY 138883 A MY138883 A MY 138883A MY PI20003987 A MYPI20003987 A MY PI20003987A MY PI20003987 A MYPI20003987 A MY PI20003987A MY 138883 A MY138883 A MY 138883A
Authority
MY
Malaysia
Prior art keywords
treatment
cencer
asiatic acid
asiatic
acid
Prior art date
Application number
MYPI20003987A
Other languages
English (en)
Inventor
Se-Kyung Oh
Chokyun Rha
Azizol Abdul Kadir
Lean Teik Ng
Original Assignee
Government Of Malaysia As Represented By The Ministry Of Science Tehnology And Innovation Malaysia
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of Malaysia As Represented By The Ministry Of Science Tehnology And Innovation Malaysia, Massachusetts Inst Technology filed Critical Government Of Malaysia As Represented By The Ministry Of Science Tehnology And Innovation Malaysia
Priority to MYPI20003987A priority Critical patent/MY138883A/en
Priority to DK01920974T priority patent/DK1313462T3/da
Priority to PCT/US2001/040103 priority patent/WO2002017904A1/en
Priority to EP01920974A priority patent/EP1313462B1/en
Priority to AU2001247968A priority patent/AU2001247968A1/en
Priority to US10/362,720 priority patent/US20040097463A1/en
Priority to JP2002522878A priority patent/JP2004507496A/ja
Priority to AT01920974T priority patent/ATE415962T1/de
Priority to DE60136826T priority patent/DE60136826D1/de
Publication of MY138883A publication Critical patent/MY138883A/en
Priority to JP2011256721A priority patent/JP5421340B2/ja

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739Lipopolysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI20003987A 2000-08-29 2000-08-29 Use of asiatic acid for treatment of cencer MY138883A (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
MYPI20003987A MY138883A (en) 2000-08-29 2000-08-29 Use of asiatic acid for treatment of cencer
DK01920974T DK1313462T3 (da) 2000-08-29 2001-02-14 Anvendelse af asiatisk syre eller asiaticosid til behandling af cancer
PCT/US2001/040103 WO2002017904A1 (en) 2000-08-29 2001-02-14 Use of asiatic acid or asiaticoside for treatment of cancer
EP01920974A EP1313462B1 (en) 2000-08-29 2001-02-14 Use of asiatic acid or asiaticoside for treatment of cancer
AU2001247968A AU2001247968A1 (en) 2000-08-29 2001-02-14 Use of asiatic acid or asiaticoside for treatment of cancer
US10/362,720 US20040097463A1 (en) 2000-08-29 2001-02-14 Use of asiatic acid or asiaticoside for treatment of cancer
JP2002522878A JP2004507496A (ja) 2000-08-29 2001-02-14 癌治療のためのアジア酸またはアジアチコサイドの使用。
AT01920974T ATE415962T1 (de) 2000-08-29 2001-02-14 Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE60136826T DE60136826D1 (de) 2000-08-29 2001-02-14 Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
JP2011256721A JP5421340B2 (ja) 2000-08-29 2011-11-24 癌治療のためのアジア酸またはアジアチコサイドの使用。

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI20003987A MY138883A (en) 2000-08-29 2000-08-29 Use of asiatic acid for treatment of cencer

Publications (1)

Publication Number Publication Date
MY138883A true MY138883A (en) 2009-08-28

Family

ID=19749475

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20003987A MY138883A (en) 2000-08-29 2000-08-29 Use of asiatic acid for treatment of cencer

Country Status (9)

Country Link
US (1) US20040097463A1 (enExample)
EP (1) EP1313462B1 (enExample)
JP (2) JP2004507496A (enExample)
AT (1) ATE415962T1 (enExample)
AU (1) AU2001247968A1 (enExample)
DE (1) DE60136826D1 (enExample)
DK (1) DK1313462T3 (enExample)
MY (1) MY138883A (enExample)
WO (1) WO2002017904A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144312A1 (en) * 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
KR100571886B1 (ko) 2004-02-23 2006-04-17 학교법인 영남학원 아시아틱산을 포함하는 피부암 예방 또는 치료용 조성물
ES2368741T3 (es) 2004-02-25 2011-11-21 Dana-Farber Cancer Institute, Inc. Inhibidores del receptor 1 del factor de crecimiento de tipo insulina para inhibir el crecimiento de células tumorales.
WO2006012015A2 (en) * 2004-06-29 2006-02-02 Oregon Health And Science University Methods and compositions for nerve regeneration
US20070010459A1 (en) * 2005-01-14 2007-01-11 Ying Liu Application of asiatic acid and its derivatives to treat pulmonary fibrosis
CA2595749A1 (en) * 2005-01-27 2006-08-03 Research Development Foundation Combination therapy with triterpenoid compounds and proteasome inhibitors
US8742167B2 (en) 2008-01-11 2014-06-03 Shanghai Institute Of Pharmaceutical Industry Therapeutic formulations based on asiatic acid and selected salts thereof
EP3062106B1 (en) 2008-04-16 2020-11-11 The Johns Hopkins University Method for determining androgen receptor variants in prostate cancer
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
WO2011077272A1 (en) 2009-12-21 2011-06-30 Pirelli Tyre S.P.A. Process and plant for building tyres
CN103079573B (zh) * 2010-06-10 2016-06-15 梧桐生物技术私人有限公司 用于由积雪草制备高纯度积雪草苷组合物的方法及其应用方法
TR201816243T4 (tr) * 2011-01-31 2018-11-21 Lucolas M D Ltd Aromataz inhibitörlerinin ve antioksidanların kombinasyonları.
US20140194368A1 (en) * 2013-01-04 2014-07-10 Beech Tree Labs, Inc. Method of Treating Cancer by Administration of Low Levels of Heat Shock Protein 70 (HSP70)
EP2968370A4 (en) 2013-03-14 2016-09-21 Univ Maryland AGENT FOR ANDROGEN RECEPTOR DOWNWARD CONTROL AND USES THEREOF
BR112015027291A8 (pt) * 2013-05-03 2019-12-24 Selecta Biosciences Inc uso de um imunossupressor que têm uma vida eficaz farmacodinâmica especificada e composição compreendendo o referido imunossupressor
EP3033088A4 (en) 2013-08-12 2017-03-08 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US10774387B2 (en) 2014-05-19 2020-09-15 The Johns Hopkins University Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
EP3186393A4 (en) * 2014-08-25 2018-01-10 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
EP3124047A1 (en) * 2015-07-28 2017-02-01 Merz Pharma GmbH & Co. KGaA Pentacyclic triterpenoids for injection lipolysis
US20180228815A1 (en) * 2016-11-09 2018-08-16 The Chinese University Of Hong Kong Naringenin and asiatic acid combination treatment of cancers
KR102753928B1 (ko) 2017-03-11 2025-01-14 셀렉타 바이오사이언시즈, 인크. 항염증제, 및 면역억제제를 포함하는 합성 나노담체를 사용한 조합 치료와 관련된 방법 및 조성물
WO2019200585A1 (en) * 2018-04-19 2019-10-24 The Chinese University Of Hong Kong Naringenin and asiatic acid combination treatment of cancers
CN113039203A (zh) * 2018-10-18 2021-06-25 中国抗体制药有限公司 通过破坏siglec型抗原的顺式配体结合调节自身免疫的方法
CN109528735B (zh) * 2019-01-30 2021-03-12 中国药科大学 积雪草苷在制备治疗皮肤癌药物中的新用途
EP3980784A1 (en) 2019-06-04 2022-04-13 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
CN110200981A (zh) * 2019-06-06 2019-09-06 中国药科大学 五环三萜皂苷的医药用途及其药物组合物
US20240034788A1 (en) * 2020-08-20 2024-02-01 The Board Of Trustees Of The Leland Stanford Junior University Abscopal therapy for cancer
WO2025188669A1 (en) * 2024-03-04 2025-09-12 Cardiff Oncology, Inc. Use of plk1 inhibitor as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB923414A (en) * 1960-04-13 1963-04-10 Laroche Navarron Lab Therapeutic compositions comprising asiatic and arjunolic acids
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
EP0383171A3 (en) * 1989-02-11 1991-07-24 Hoechst Aktiengesellschaft 2,3,23-trihydroxy-urs-12-ene derivatives for treating cognitive disorders
FR2714598B1 (fr) * 1993-12-30 1996-02-09 Oreal Composition amincissante à deux types de liposomes pour traitement topique, son utilisation.
JPH08133952A (ja) * 1994-11-07 1996-05-28 Shiseido Co Ltd 皮膚外用剤
DE69705238T2 (de) * 1996-11-27 2002-04-18 Dong Kook Pharmaceutical Co., Ltd. Derivate der asiatica-saeure mit einem modifizierten a-ring
IT1288257B1 (it) * 1996-11-29 1998-09-11 Paoli Ambrosi Gianfranco De Composizione per uso cosmetico,farmaceutico o dietetico a base di un aminozucchero e/o di un acido poliidrossilico
FR2763336B1 (fr) * 1997-05-14 1999-08-06 Lvmh Rech Esters de tocopherol et leurs utilisations en cosmetique et pharmacie
RU2007101074A (ru) * 2004-06-14 2008-07-20 Зозер Б. САЛАМА (DE) Фармацевтическая противораковая композиция пролина или его производных и противоопухолевого антитела

Also Published As

Publication number Publication date
JP5421340B2 (ja) 2014-02-19
EP1313462B1 (en) 2008-12-03
DE60136826D1 (de) 2009-01-15
US20040097463A1 (en) 2004-05-20
WO2002017904A1 (en) 2002-03-07
AU2001247968A1 (en) 2002-03-13
DK1313462T3 (da) 2009-03-30
JP2004507496A (ja) 2004-03-11
JP2012092110A (ja) 2012-05-17
ATE415962T1 (de) 2008-12-15
EP1313462A1 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
AU7031500A (en) Therapeutic quinazoline compounds
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
AU6998791A (en) Use of n-myristoyl-(s)-phenylalanine for obtaining medicinal products intended for the treatment of diseases involving myristoylation
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
SG144712A1 (en) Nordihydroguaiartic derivaties for use in treatment of tumors
MY164077A (en) Compositions and uses of et743 for treating cancer
AU2002239491A1 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
GB9521608D0 (en) Pharmaceutical composition
CA2227711A1 (en) Thioctic acid metabolites and methods of use thereof
GB9907571D0 (en) Compounds
GB9923078D0 (en) Sapogenin derivatives and their use
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
AU2002352566A1 (en) Use of corrinoids in the treatment of skin diseases
DE60006284D1 (de) Arzneimittel zur behandlung konvulsivischer zustände
GB9723824D0 (en) Cytostatic agents
AU2450900A (en) Therapeutic nucleoside compound
UA32241A (uk) Спосіб лікування запалювальних процесів у експериментальних тварин
MXPA02000485A (es) 2-amino-benzoxazinonas para el tratamiento del virus de herpes simple.
UA32315A (uk) Спосіб накладання шкірного шва
MXPA03004074A (es) Derivados de retiferol y su uso en el tratamiento de enfermedades o trastornos de la piel asociadas con fotoda°o.
AUPR171000A0 (en) Composition for the treatment of infectious and/or skin diseases